FDAsafety guidance66% confidence
FDA AP — WEGOVY (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Novo Nordisk; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA215256. Sponsor: NOVO. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: SEMAGLUTIDE.
Supporting Context
- Therapeutic area
- Diabetes · GLP-1 Agonist
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for Ozempic (Semaglutide)